Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers
Autor: | Dekhnich A.V., Zubareva N.A., Kozlov R.S., Popov D.A., Romanov A.V., Rudnov V.A. |
---|---|
Jazyk: | ruština |
Rok vydání: | 2015 |
Předmět: | |
Zdroj: | Клиническая микробиология и антимикробная химиотерапия, Vol 17, Iss 2, Pp 127-145 (2015) |
Druh dokumentu: | article |
ISSN: | 1684-4386 2686-9586 |
Popis: | Telavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) microorganisms, including multiresistant strains. Another perspective area of telavancin use — bloodstream infections, such as bacteremia and endocarditis. Telavancin is in vitro active against broad range of Gram(+) aerobic and anaerobic bacteria, including strains resistant to other antimicrobials: MRSA, MRSE, VISA, daptomycin non-susceptible strains of S. aureus, penicillin-resistant S. pneumoniae, ampicillin-resistant enterococci and enterococci with VanB phenotype of resistance to vancomycin. Talavancin is rapidly bactericidal due to its dual mechanism of action; it is active against intracellular bacterial cells and biofilmforming cells. Article reviews data of current in vitro and in vivo studies of telavancin, as well as clinical trials results. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |